Earnings Report Update: Free Research on Fate Therapeutics, La Jolla,FONAR, TASER, and Allied Motion
NEW YORK, April 23, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Fate Therapeutics, Inc. (NASDAQ: FATE), La Jolla Pharmaceutical Company. (NASDAQ: LJPC), FONAR Corporation (NASDAQ: FONR), TASER International, Inc. (NASDAQ:TASR), and Allied Motion Technologies, Inc. (NASDAQ: AMOT). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
FATE Research Report: ( http://get.analystsreview.com/pdf/?c=Fate%20Therapeutics&d=23-Apr-2015&s=FATE ),
LJPC Research Report: ( http://get.analystsreview.com/pdf/?c=La%20Jolla&d=23-Apr-2015&s=LJPC ),
FONR Research Report: ( http://get.analystsreview.com/pdf/?c=FONAR&d=23-Apr-2015&s=FONR ),
TASR Research Report: ( http://get.analystsreview.com/pdf/?c=TASER&d=23-Apr-2015&s=TASR ),
AMOT Research Report: ( http://get.analystsreview.com/pdf/?c=Allied%20Motion&d=23-Apr-2015&s=AMOT ).
============
--
Financial Results, Appointments, and New Orders
Analyst Update: Reviewed by: Rohit Tuli, CFA®
U.S. stocks edged higher on Wednesday as better than expected earnings and strong existing home sales data bolstered investor sentiment. The NASDAQ advanced 0.42% to finish at 5,035.17, its third straight gain and just 13 points below its record close reached on March 10, 2000. The Dow Jones Industrial Average rose 0.49% or 88.35 points to 18,038.27, and the S&P 500 gained 0.50%, or 9.69 points to close the session at 2107.96. European stocks closed with a mixed note on Wednesday, depressed by increasing concern over Greece's bailout negotiations and disappointing earnings. Germany's DAX and Britain's FTSE 100 index slipped 0.6% and 0.5%, respectively, while France's CAC gained 0.36% on Wednesday. Meanwhile, Asian market continued their good run with The Shanghai Composite and Japan's Nikkei closing at new multi-year highs on Wednesday.
Fate Therapeutics, Inc. (Fate Therapeutics) announced its 2014 financial results along with update on its recent program developments & upcoming milestones. Net loss and comprehensive loss for 2014 narrowed to $6.2 million versus $5.7 million in 2013. Cash and cash equivalents as of December 31, 2014 were $49.1 million, compared to $54.0 million as of December 31, 2013.
La Jolla Pharmaceutical Company (La Jolla), announced addition of four new members to its advisory board for the development of LJPC-401, its novel formulation of hepcidin. The new members of the advisory board are Paul Adams, M.D., Victor Gordeuk, M.D., Ashutosh Lal, M.D., and Gordon McLaren, M.D.
FONAR Corporation (FONAR), the first Company in the MRI industry to manufacture a Magnetic Resonance Imaging scanner reported a 24% YoY increase to $2.5 million in its net Income available to common stockholders for Q2 FY 2015. Net Revenues for the quarter stood at $17.1 million versus $17.6 million in the same period a year earlier.
TASER International, Inc. (TASER) announced the purchase of 300 AXON Flex body cameras and a five-year subscription on the EVIDENCE.com Officer Safety Plan by the Alabama's Mobile Police Department. This order is expected to ship in the second quarter of 2015.
Allied Motion Technologies, Inc. (Allied Motion) announced its Q4 2014 and full year 2014 financial results. For the quarter, net income increased to $4.9 million or $0.53 per diluted share from $1.3 million or $0.15 per diluted share in Q4 2013. Revenues for the quarter increased 23% YoY to $61.9 million.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article